Medipolis GMP, a Finnish company based in Oulu, and Bioton SA, a Polish pharmaceutical company, have signed a licensing agreement on the manufacturing technology research project of an insulin analog used in treating diabetes.
The Finnish biopharmaceutical company Medipolis GMP Ltd and the Polish pharmaceutical company Bioton SA have concluded a technology licensing agreement. The agreement is worth EUR 5.3 million and is the final breakthrough for Medipolis GMP’s insulin analog manufacturing method that is a solution for producing more affordable alternatives to a growing global health problem.
The agreement includes a technology transfer agreement regarding Medipolis GMP’s manufacturing technology research project for producing a biologically active drug, a human insulin analog. With the agreement, Medipolis GMP grants Bioton a license for using its technology for further research and development and later for manufacturing and commercial purposes.
Diabetes is one of the greatest public health challenges in the world. According to latest estimates, 250 million adults worldwide have diabetes. By 2025, the number is estimated to increase up to 400 million. The alternative insulin analog research by Medipolis provides diabetes care with new and more affordable alternatives.
“This biosimilar development project will help bring us affordable healthcare for by providing more economical technologies for the production of off-patentent biologics”, says Director of Biopharmaceuticals, Dr. Ashesh Kumar, the head of the project.
Within Finland, the insulin analog research by Medipolis GMP is a unique innovation since the country does not have an industry producing biosimilar medicines.
“This is a major breakthrough for an Oulu-based biopharmaceutical company”, says Vice Rector, Professor Taina Pihlajaniemi from the University of Oulu. “Medipolis GMP’s determined drug development work and its commitment to the project have been impressive. The core competence of the University of Oulu Biocenter has been utilized in the development process, and Oulu’s strong medical and bioscience know-how and regional infrastructure have also supported the work well.”
Medipolis GMP is a Finnish Oulu-based biopharmaceutical company that has focused its recent activities on biologics process development and process optimization. In Oulu, it has a fully equipped and approved cGMP manufacturing facility specialized in biologics production.
Source: The Herald